Laura Wegener Parfrey

Laura Wegener Parfrey

Auto-generated profile, based on publicly available information

Laura Wegener Parfrey

The University of British Columbia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2015 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JLJulius Lukeš
Julius Lukeš
CSChristen Rune Stensvold
Christen Rune Stensvold
K(Kateřina Jirků (Pomajbíková)
Kateřina Jirků (Pomajbíková)
LPLaura Wegener Parfrey
Laura Wegener Parfrey

19 June 2014 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
LPLaura Wegener Parfrey
Laura Wegener Parfrey
WWWilliam A. Walters
William A. Walters
CLChristian L. Lauber
Christian L. Lauber
JCJose C. Clemente
Jose C. Clemente
DBDonna Berg-Lyons
Donna Berg-Lyons
RKRob Knight
Rob Knight
Eukaryotic microbes (protists) residing in the vertebrate gut influence host health and disease, but their diversity and distribution in healthy hosts is poorly understood. Protists found in the gut are typically considered parasites, but many are commensal and some are beneficial. Further, the hygiene hypothesis predicts that association with our co-evolved microbial symbionts may be important to overall health. It is therefore imperative that we understand the normal diversity of our eukaryotic gut microbiota to test for such effects and avoid eliminating commensal organisms. We assembled a dataset of healthy individuals from two populations, one with traditional, agrarian lifestyles and a second with modern, westernized lifestyles, and characterized the human eukaryotic microbiota via high-throughput sequencing. To place the human gut microbiota within a broader context our dataset also includes gut samples from diverse mammals and samples from other aquatic and terrestrial environments. We curated the SILVA ribosomal database to reflect current knowledge of eukaryotic taxonomy and employ it as a phylogenetic framework to compare eukaryotic diversity across environment. We show that adults from the non-western population harbor a diverse community of protists, and diversity in the human gut is comparable to that in other mammals. However, the eukaryotic microbiota of the western population appears depauperate. The distribution of symbionts found in mammals reflects both host phylogeny and diet. Eukaryotic microbiota in the gut are less diverse and more patchily distributed than bacteria. More broadly, we show that eukaryotic communities in the gut are less diverse than in aquatic and terrestrial habitats, and few taxa are shared across habitat types, and diversity patterns of eukaryotes are correlated with those observed for bacteria. These results outline the distribution and diversity of microbial eukaryotic communities in the mammalian gut and across environments.

30 July 2018 in Nature Ecology & Evolution
Verified
Journal Article
Closed access
PDF file
SLStilianos Louca
Stilianos Louca
PSPatrick M. Shih
Patrick M. Shih
MPMatthew W. Pennell
Matthew W. Pennell
WFWoodward W. Fischer
Woodward W. Fischer
LPLaura Wegener Parfrey
Laura Wegener Parfrey
MDMichael Doebeli
Michael Doebeli

1 April 2018 in Molecular Ecology
Verified
Journal Article
Closed access
PDF file
LPLaura Wegener Parfrey
Laura Wegener Parfrey
CMCorrie S. Moreau
Corrie S. Moreau
JRJacob A. Russell
Jacob A. Russell

20 August 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JLJordan D. Lin
Jordan D. Lin
MLMatthew A. Lemay
Matthew A. Lemay
LPLaura W. Parfrey
Laura W. Parfrey
Bacteria are integral to marine carbon cycling. They transfer organic carbon to higher trophic levels and remineralise it into inorganic forms. Kelp forests are among the most productive ecosystems within the global oceans, yet the diversity and metabolic capacity of bacteria that transform kelp carbon is poorly understood. Here, we use 16S amplicon and metagenomic shotgun sequencing to survey bacterial communities associated with the surfaces of the giant kelp Macrocystis pyrifera and assess the capacity of these bacteria for carbohydrate metabolism. We find that Macrocystis-associated communities are distinct from the water column, and that they become more diverse and shift in composition with blade depth, which is a proxy for tissue age. These patterns are also observed in metagenomic functional profiles, though the broader functional groups—carbohydrate active enzyme families—are largely consistent across samples and depths. Additionally, we assayed more than 250 isolates cultured from Macrocystis blades and the surrounding water column for the ability to utilize alginate, the primary polysaccharide in Macrocystis tissue. The majority of cultured bacteria (66%) demonstrated this capacity; we find that alginate utilization is patchily distributed across diverse genera in the Bacteroidetes and Proteobacteria, yet can also vary between isolates with identical 16S rRNA sequences. The genes encoding enzymes involved in alginate metabolism were detected in metagenomic data across taxonomically diverse bacterial communities, further indicating this capacity is likely widespread amongst bacteria in kelp forests. Overall, the M. pyrifera epibiota shifts across a depth gradient, demonstrating a connection between bacterial assemblage and host tissue state.

19 July 2018 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
Jean-Michel HeraudJean-Michel Heraud
Jean-Michel Heraud
PVPascale Vonaesch
Pascale Vonaesch
RRRindra Vatosoa Randremanana
Rindra Vatosoa Randremanana
JGJean-Chrysostome Gody
Jean-Chrysostome Gody
JCJean-Marc Collard
Jean-Marc Collard
PSPhilippe J. Sansonetti
Philippe J. Sansonetti
Globally one out of four children under 5 years is affected by linear growth delay (stunting). This syndrome has severe long-term sequelae including increased risk of illness and mortality and delayed psychomotor development. Stunting is a syndrome that is linked to poor nutrition and repeated infections. To date, the treatment of stunted children is challenging as the underlying etiology and pathophysiological mechanisms remain elusive. We hypothesize that pediatric environmental enteropathy (PEE), a chronic inflammation of the small intestine, plays a major role in the pathophysiology of stunting, failure of nutritional interventions and diminished response to oral vaccines, potentially via changes in the composition of the pro- and eukaryotic intestinal communities. The main objective of AFRIBIOTA is to describe the intestinal dysbiosis observed in the context of stunting and to link it to PEE. Secondary objectives include the identification of the broader socio-economic environment and biological and environmental risk factors for stunting and PEE as well as the testing of a set of easy-to-use candidate biomarkers for PEE. We also assess host outcomes including mucosal and systemic immunity and psychomotor development. This article describes the rationale and study protocol of the AFRIBIOTA project. AFRIBIOTA is a case-control study for stunting recruiting children in Bangui, Central African Republic and in Antananarivo, Madagascar. In each country, 460 children aged 2–5 years with no overt signs of gastrointestinal disease are recruited (260 with no growth delay, 100 moderately stunted and 100 severely stunted). We compare the intestinal microbiota composition (gastric and small intestinal aspirates; feces), the mucosal and systemic immune status and the psychomotor development of children with stunting and/or PEE compared to non-stunted controls. We also perform anthropological and epidemiological investigations of the children’s broader living conditions and assess risk factors using a standardized questionnaire. To date, the pathophysiology and risk factors of stunting and PEE have been insufficiently investigated. AFRIBIOTA will add new insights into the pathophysiology underlying stunting and PEE and in doing so will enable implementation of new biomarkers and design of evidence-based treatment strategies for these two syndromes.